Clinical trials: Moderate to Severe Asthma
Asthma, GERD
Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma
The purpose of this study is to determine whether treatment with esomeprazole for 6 months will improve asthma in adult patients with moderate to severe asthma and symptoms of gastroesophageal reflux disease.
- Trial name
- RELAX (NCT00317044)
- Testing
- Esomeprazole
- Where
- 130 sites in United States, Argentina and 12 more
- Volunteers
- 961 people
- Sponsor
- AstraZeneca
Asthma
New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma
The purpose of this study is to evaluate the long-term safety of the fixed combination asthma drug FlutiForm HFA MDI (containing fluticasone propionate and formoterol fumarate) in adult and adolescent patients with mild to…
- Trial name
- NCT00394121
- Testing
- Fluticasone propionate/formoterol fumarate
- Where
- 28 sites in Germany, Hungary and 3 more
- Volunteers
- 400 people
- Sponsor
- SkyePharma AG
Resistance Training
Chronic Effects Using Light-Emitting Diode Therapy (LEDT) During a Resistance Exercise Protocol for Asthmatic Patients
The objective of this study is to evaluate the effects of LED phototherapy associated with a resistance training protocol on the peripheral muscle function of moderate to severe asthmatic patients ..
- Trial name
- NCT03112239
- Testing
- Light-Emitting Diode Therapy (LEDT)
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- University of Nove de Julho
Asthma
Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma
This study is a two strata, dose escalation Phase I clinical trial designed to assess the safety and determine the maximal tolerated dose (MTD) of allogenic cord tissue derived MSCs (cMSCs, stratum 1) and allogeneic, interferon-γ…
- Trial name
- NCT05035862
- Testing
- Albuterol Sulfate, Interferon gamma-primed mesenchymal stromal cells (MSCs), Prednisone
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Emory University
Asthma
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
This is a study of amlitelimab for the treatment of participants with moderate-to-severe asthma. The study will have a double-blind treatment period until Week 24 for each participant and an open-label treatment period where each…
- Trial name
- RIVER-ASTHMA (NCT06033833)
- Testing
- Amlitelimab
- Where
- 68 sites in United States, Argentina and 12 more
- Volunteers
- 335 people
- Sponsor
- Sanofi
Asthma
Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma
This study was designed to assess the safety of indacaterol (300 µg and 600 µg (2 x 300 μg capsules) once daily [od]), compared with salmeterol (50 μg twice a day [b.i.d.]), over 26 weeks, in patients with moderate to severe…
- Trial name
- NCT00529529
- Testing
- Indacaterol 300 μg, Salmeterol 50 μg
- Where
- 126 sites in United States, Argentina and 10 more
- Volunteers
- 805 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled…
- Trial name
- FLASH (NCT05251259)
- Testing
- Atuliflapon
- Where
- 234 sites in United States, Argentina and 18 more
- Volunteers
- 670 people
- Sponsor
- AstraZeneca
Moderate to Severe Asthma
Study of Multiple Ascending Dose of KBL693 in Healthy Participants
The study is designed to investigate the safety and tolerability of KBL693 in healthy volunteers. KBL693 has been developed as a potential new treatment for moderate to severe asthma..
- Trial name
- NCT04307173
- Testing
- KBL693
- Where
- Australia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- KoBioLabs
Asthma
An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
Primary Objective: To evaluate the efficacy of different doses and regimens of dupilumab in participants with moderate to severe uncontrolled asthma.
- Trial name
- NCT01854047
- Testing
- Dupilumab, ICS/LABA therapy, Salbutamol/albuterol
- Where
- 201 sites in United States, Argentina and 14 more
- Volunteers
- 776 people
- Sponsor
- Sanofi
Allergic Asthma
A Study to Evaluate the Safety and Efficacy of HAE1 in Subjects With Moderate to Severe Allergic Asthma
This is a Phase II, multicenter, randomized, double blind, placebo controlled, multiple-dose study designed to evaluate the efficacy, safety, and tolerability of subcutaneously administered HAE1 in subjects 12-75 years old with…
- Trial name
- NCT00406965
- Testing
- HAE1 (PRO98498)
- Volunteers
- 50 people
- Sponsor
- Genentech, Inc.
Asthma
Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.
This is a comparative bioavailability study to compare the pharmacokinetics and pharmacodynamic effects of Fluticasone propionate and Salmeterol delivered in a capsule-based inhaler versus a multi-dose dry powder inhaler in…
- Trial name
- NCT01494610
- Testing
- SERETIDE Rotacaps, SERETIDE Diskus
- Where
- 2 sites in Australia, New Zealand
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Asthma
A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.
The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration, FDA) in the African American population.
- Trial name
- NCT00419952
- Testing
- Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI
- Where
- 122 sites in United States
- Volunteers
- 742 people
- Sponsor
- AstraZeneca
Asthma
A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults
The medications being used in this study are individually approved by the Food and Drug Administration (FDA). The medication under investigation is a combination of two medications in one inhaler.
- Trial name
- NCT00649025
- Testing
- FlutiForm 250/10, SKP-Fluticasone, Flovent Fluticasone HFA
- Where
- 103 sites in United States, Argentina and 8 more
- Volunteers
- 438 people
- Sponsor
- SkyePharma AG
Asthma
Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years
A double blind, double dummy, randomised, multicentre, two arm parallel group study to assess the efficacy and safety of FLUTIFORM® pMDI (2 puffs bid) vs Seretide® pMDI (2 puffs bid) in subjects aged ≥12 years with moderate to…
- Trial name
- NCT03387241
- Testing
- Fluticasone/ Formoterol, fluticasone/ salmeterol
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Asthma
Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.
This study will evaluate the safety and efficacy of omalizumab up to 48 weeks in adult patients with moderate to severe bronchial asthma. THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES
- Trial name
- NCT00219323
- Testing
- Omalizumab
- Where
- Japan
- Volunteers
- 133 people
- Sponsor
- Novartis
Moderate-to-Severe Asthma
Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids
This study will evaluate the safety, tolerability and efficacy of a single dose level of KB003 in subjects with inadequately controlled asthma.
- Trial name
- KB003-04 (NCT01603277)
- Testing
- Anti-GM-CSF Monoclonal Antibody 400mg
- Where
- 70 sites in United States, Australia and 4 more
- Volunteers
- 160 people
- Sponsor
- Humanigen, Inc.
Asthma in Children
Double Dose Magnesium Sulphate in Moderate-severe Asthma in Paediatrics
Introduction : . In Oman the prevalence of asthma was estimated to be 7.3% of adults and 12.7% of children . Magnesium sulphate is the second line treatment, many studies had shown that it has beneficial effect in treating acute…
- Trial name
- NCT04465175
- Testing
- Magnesium Sulfate
- Volunteers
- 90 people
- Sponsor
- Oman Medical Speciality Board
Asthma (Diagnosis), Breathlessness
Multicomponent Breathlessness and Physical Activity Intervention in People With Asthma Using a Digital Platform
Treating breathlessness could help people with asthma have fewer symptoms and be more physically active. People with asthma report that it is important to deal with breathlessness during physical activity programs, but past…
- Trial name
- BRAID (NCT07421115)
- Testing
- Multicomponent digital self-management platform, Enhanced usual care
- Where
- 2 sites in Australia
- Volunteers
- 300 people
- Sponsor
- University of Newcastle, Australia
Asthma
Assessing the Efficacy of CREWS01 to Decrease Usage of Rescue Inhalers in Moderate to Severe Asthmatic Adults
This is a double-blind, randomized, placebo-controlled, proof of concept, study in adults with poorly controlled moderate to severe asthma.
- Trial name
- CREWS01 (NCT02153541)
- Testing
- Antipyrine-benzocaine otic solution, Glycerin with Oxyquinoline Sulfate
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Global United Pharmaceutical Corporation
Asthma
Airway Inflammation and Disease Burden in Asthmatic Smokers
Aim : To compare, among patients with an uncontrolled moderate to severe asthma, the blood eosinophil levels of smokers and non-smokers.
- Trial name
- NCT02833727
- Testing
- Smoking
- Where
- Canada
- Volunteers
- 160 people
- Sponsor
- Université de Montréal